The global Point-of-care Infectious Disease Diagnostics market size was valued at US$ million in 2023. With growing demand in downstream market, the Point-of-care Infectious Disease Diagnostics is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Point-of-care Infectious Disease Diagnostics market. Point-of-care Infectious Disease Diagnostics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Point-of-care Infectious Disease Diagnostics. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Point-of-care Infectious Disease Diagnostics market.
Point of care diagnosis allows for early detection of diseases and can greatly impact the medical outcome of the disease treatment.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Point-of-care Infectious Disease Diagnostics market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Point-of-care Infectious Disease Diagnostics market. It may include historical data, market segmentation by Type (e.g., HIV POC, Clostridium Difficile POC), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Point-of-care Infectious Disease Diagnostics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Point-of-care Infectious Disease Diagnostics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Point-of-care Infectious Disease Diagnostics industry. This include advancements in Point-of-care Infectious Disease Diagnostics technology, Point-of-care Infectious Disease Diagnostics new entrants, Point-of-care Infectious Disease Diagnostics new investment, and other innovations that are shaping the future of Point-of-care Infectious Disease Diagnostics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Point-of-care Infectious Disease Diagnostics market. It includes factors influencing customer ' purchasing decisions, preferences for Point-of-care Infectious Disease Diagnostics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Point-of-care Infectious Disease Diagnostics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Point-of-care Infectious Disease Diagnostics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Point-of-care Infectious Disease Diagnostics market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Point-of-care Infectious Disease Diagnostics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Point-of-care Infectious Disease Diagnostics market.
麻豆原创 Segmentation:
Point-of-care Infectious Disease Diagnostics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
HIV POC
Clostridium Difficile POC
HBV POC
Respiratory Syncytial Virus POC
HPV POC
Influenza/Flu POC
HCV POC
MRSA POC
TB and Drug-Resistant TB POC
Segmentation by application
Hospitals
Clinics
麻豆原创
Assisted Living Healthcare Facilities
Laboratories
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Thermo Fisher Scientific
Abbott
Calypte Biomedical
Chembio Diagnostic Systems
Meridian Bioscience
MedMira
Trinity Biotech
Sekisui Diagnostics
OraSure Technologies
Quidel
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Point-of-care Infectious Disease Diagnostics 麻豆原创 Size 2019-2030
2.1.2 Point-of-care Infectious Disease Diagnostics 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Point-of-care Infectious Disease Diagnostics Segment by Type
2.2.1 HIV POC
2.2.2 Clostridium Difficile POC
2.2.3 HBV POC
2.2.4 Respiratory Syncytial Virus POC
2.2.5 HPV POC
2.2.6 Influenza/Flu POC
2.2.7 HCV POC
2.2.8 MRSA POC
2.2.9 TB and Drug-Resistant TB POC
2.3 Point-of-care Infectious Disease Diagnostics 麻豆原创 Size by Type
2.3.1 Point-of-care Infectious Disease Diagnostics 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Point-of-care Infectious Disease Diagnostics 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Point-of-care Infectious Disease Diagnostics Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 麻豆原创
2.4.4 Assisted Living Healthcare Facilities
2.4.5 Laboratories
2.4.6 Others
2.5 Point-of-care Infectious Disease Diagnostics 麻豆原创 Size by Application
2.5.1 Point-of-care Infectious Disease Diagnostics 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Point-of-care Infectious Disease Diagnostics 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Point-of-care Infectious Disease Diagnostics 麻豆原创 Size by Player
3.1 Point-of-care Infectious Disease Diagnostics 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Point-of-care Infectious Disease Diagnostics Revenue by Players (2019-2024)
3.1.2 Global Point-of-care Infectious Disease Diagnostics Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Point-of-care Infectious Disease Diagnostics Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Point-of-care Infectious Disease Diagnostics by Regions
4.1 Point-of-care Infectious Disease Diagnostics 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Point-of-care Infectious Disease Diagnostics 麻豆原创 Size Growth (2019-2024)
4.3 APAC Point-of-care Infectious Disease Diagnostics 麻豆原创 Size Growth (2019-2024)
4.4 Europe Point-of-care Infectious Disease Diagnostics 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Point-of-care Infectious Disease Diagnostics 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Point-of-care Infectious Disease Diagnostics 麻豆原创 Size by Country (2019-2024)
5.2 Americas Point-of-care Infectious Disease Diagnostics 麻豆原创 Size by Type (2019-2024)
5.3 Americas Point-of-care Infectious Disease Diagnostics 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Point-of-care Infectious Disease Diagnostics 麻豆原创 Size by Region (2019-2024)
6.2 APAC Point-of-care Infectious Disease Diagnostics 麻豆原创 Size by Type (2019-2024)
6.3 APAC Point-of-care Infectious Disease Diagnostics 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Point-of-care Infectious Disease Diagnostics by Country (2019-2024)
7.2 Europe Point-of-care Infectious Disease Diagnostics 麻豆原创 Size by Type (2019-2024)
7.3 Europe Point-of-care Infectious Disease Diagnostics 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Point-of-care Infectious Disease Diagnostics by Region (2019-2024)
8.2 Middle East & Africa Point-of-care Infectious Disease Diagnostics 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Point-of-care Infectious Disease Diagnostics 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.1 Global Point-of-care Infectious Disease Diagnostics Forecast by Regions (2025-2030)
10.1.1 Global Point-of-care Infectious Disease Diagnostics Forecast by Regions (2025-2030)
10.1.2 Americas Point-of-care Infectious Disease Diagnostics Forecast
10.1.3 APAC Point-of-care Infectious Disease Diagnostics Forecast
10.1.4 Europe Point-of-care Infectious Disease Diagnostics Forecast
10.1.5 Middle East & Africa Point-of-care Infectious Disease Diagnostics Forecast
10.2 Americas Point-of-care Infectious Disease Diagnostics Forecast by Country (2025-2030)
10.2.1 United States Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.2.2 Canada Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.2.3 Mexico Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.2.4 Brazil Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.3 APAC Point-of-care Infectious Disease Diagnostics Forecast by Region (2025-2030)
10.3.1 China Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.3.2 Japan Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.3.3 Korea Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.3.4 Southeast Asia Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.3.5 India Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.3.6 Australia Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.4 Europe Point-of-care Infectious Disease Diagnostics Forecast by Country (2025-2030)
10.4.1 Germany Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.4.2 France Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.4.3 UK Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.4.4 Italy Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.4.5 Russia Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.5 Middle East & Africa Point-of-care Infectious Disease Diagnostics Forecast by Region (2025-2030)
10.5.1 Egypt Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.5.2 South Africa Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.5.3 Israel Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.5.4 Turkey Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.5.5 GCC Countries Point-of-care Infectious Disease Diagnostics 麻豆原创 Forecast
10.6 Global Point-of-care Infectious Disease Diagnostics Forecast by Type (2025-2030)
10.7 Global Point-of-care Infectious Disease Diagnostics Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Information
11.1.2 Thermo Fisher Scientific Point-of-care Infectious Disease Diagnostics Product Offered
11.1.3 Thermo Fisher Scientific Point-of-care Infectious Disease Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Thermo Fisher Scientific Main Business Overview
11.1.5 Thermo Fisher Scientific Latest Developments
11.2 Abbott
11.2.1 Abbott Company Information
11.2.2 Abbott Point-of-care Infectious Disease Diagnostics Product Offered
11.2.3 Abbott Point-of-care Infectious Disease Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Abbott Main Business Overview
11.2.5 Abbott Latest Developments
11.3 Calypte Biomedical
11.3.1 Calypte Biomedical Company Information
11.3.2 Calypte Biomedical Point-of-care Infectious Disease Diagnostics Product Offered
11.3.3 Calypte Biomedical Point-of-care Infectious Disease Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Calypte Biomedical Main Business Overview
11.3.5 Calypte Biomedical Latest Developments
11.4 Chembio Diagnostic Systems
11.4.1 Chembio Diagnostic Systems Company Information
11.4.2 Chembio Diagnostic Systems Point-of-care Infectious Disease Diagnostics Product Offered
11.4.3 Chembio Diagnostic Systems Point-of-care Infectious Disease Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Chembio Diagnostic Systems Main Business Overview
11.4.5 Chembio Diagnostic Systems Latest Developments
11.5 Meridian Bioscience
11.5.1 Meridian Bioscience Company Information
11.5.2 Meridian Bioscience Point-of-care Infectious Disease Diagnostics Product Offered
11.5.3 Meridian Bioscience Point-of-care Infectious Disease Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Meridian Bioscience Main Business Overview
11.5.5 Meridian Bioscience Latest Developments
11.6 MedMira
11.6.1 MedMira Company Information
11.6.2 MedMira Point-of-care Infectious Disease Diagnostics Product Offered
11.6.3 MedMira Point-of-care Infectious Disease Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 MedMira Main Business Overview
11.6.5 MedMira Latest Developments
11.7 Trinity Biotech
11.7.1 Trinity Biotech Company Information
11.7.2 Trinity Biotech Point-of-care Infectious Disease Diagnostics Product Offered
11.7.3 Trinity Biotech Point-of-care Infectious Disease Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Trinity Biotech Main Business Overview
11.7.5 Trinity Biotech Latest Developments
11.8 Sekisui Diagnostics
11.8.1 Sekisui Diagnostics Company Information
11.8.2 Sekisui Diagnostics Point-of-care Infectious Disease Diagnostics Product Offered
11.8.3 Sekisui Diagnostics Point-of-care Infectious Disease Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Sekisui Diagnostics Main Business Overview
11.8.5 Sekisui Diagnostics Latest Developments
11.9 OraSure Technologies
11.9.1 OraSure Technologies Company Information
11.9.2 OraSure Technologies Point-of-care Infectious Disease Diagnostics Product Offered
11.9.3 OraSure Technologies Point-of-care Infectious Disease Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 OraSure Technologies Main Business Overview
11.9.5 OraSure Technologies Latest Developments
11.10 Quidel
11.10.1 Quidel Company Information
11.10.2 Quidel Point-of-care Infectious Disease Diagnostics Product Offered
11.10.3 Quidel Point-of-care Infectious Disease Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Quidel Main Business Overview
11.10.5 Quidel Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
